BackMerrimack Pharmaceuticals Overview

Merrimack Pharmaceuticals Receivables

Latest receivables for MACK: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Merrimack Pharmaceuticals Receivables History

Loading

Merrimack Pharmaceuticals vs. peers: Receivables Comparison

Loading

Merrimack Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Merrimack Pharmaceuticals (MACK) FAQ

As of the most recent data (March 2024), MACK shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MACK's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Merrimack Pharmaceuticals is outperforming or lagging.

Tracking MACK's receivables over time shows whether Merrimack Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Merrimack Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Merrimack Pharmaceuticals's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.